Durvalumab Plus Tremelimumab for First-Line Treatment of Hepatocellular Carcinoma – Gastroenterology & Hepatology
Robin Kate Kelley, MD Professor of Clinical Medicine Division of Hematology/Oncology Helen Diller Family Comprehensive Cancer Center University of California, San Francisco San Francisco, California G & H What is the rationale for using durvalumab and tremelimumab in combination for the treatment of hepatocellular carcinoma? RK Durvalumab (Imfinzi, AstraZeneca) and tremelimumab (Imjudo, AstraZeneca) are both immune checkpoint inhibitors, but different ones. Durvalumab is an inhibitor of the programmed